Vericel Raises MACI Guidance on Record First Quarter

Vericel's MACI orthobiologic

Vericel reported 1Q21 orthopedic revenue of USD $23.8 million, +17.3% vs. 1Q20. The company notched its best-ever first quarter, leading it to increase 2021 MACI growth guidance to the mid-30% range. Vericel has high expectations for MACI in the second half of the year given current biopsy rates from surgeons.

MACI biopsy volumes, the...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us